Skip to main content

Advertisement

SpringerLink
Log in

EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

Additional data pertaining to this case is available upon request.

References

  1. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL et al (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128(2):260–270

    Article  CAS  Google Scholar 

  2. Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B et al (2001) High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98(6):1721–1726

    Article  CAS  Google Scholar 

  3. Ammatuna E, Sarlo C, Ottaviani L, Quaresima M, Buccisano F, Campagna S et al (2009) Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia. Leuk Lymphoma 50(5):857–858

    Article  CAS  Google Scholar 

  4. van de Langerijt B, Doorduijn JK, Lam KH, van den Bent MJ (2011) EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab. J Neurol 258(5):944–945

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Toronto, Toronto, ON, Canada

    Adam Suleman, Philip W. Lam & Lee Mozessohn

  2. Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Hubert Tsui & Zeina Ghorab

  3. Department of Immunology, University of Toronto, Toronto, ON, Canada

    Hubert Tsui

  4. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

    Zeina Ghorab

  5. Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Philip W. Lam

  6. Division of Hematology/Medical Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada

    Lee Mozessohn

Authors
  1. Adam Suleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hubert Tsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zeina Ghorab
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philip W. Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lee Mozessohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam Suleman.

Ethics declarations

Ethics approval

This article does not contain any studies with human participants performed by any of the authors.

Consent for publication

The family of this patient provided informed consent for publication of this material.

Conflict of interest

The authors declare no conflicts of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suleman, A., Tsui, H., Ghorab, Z. et al. EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia. Ann Hematol 102, 471–472 (2023). https://doi.org/10.1007/s00277-022-05060-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-022-05060-x

Search

Navigation